metadate cd formulation Search Results


metadate cd  (UCB SA Inc)
90
UCB SA Inc metadate cd
Mean total methylphenidate plasma concentration–time profiles for <t>MPH</t> XR-ODT under fasted conditions in children and adolescents by age. MPH XR-ODT, methylphenidate extended-release orally disintegrating tablets.
Metadate Cd, supplied by UCB SA Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/metadate+cd+formulation/metadate+cd/pmc04991613-147-27-41
Average 90 stars, based on 1 article reviews
metadate cd - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
quillivant xr™  (NextWave Inc)
90
NextWave Inc quillivant xr™
Mean total methylphenidate plasma concentration–time profiles for <t>MPH</t> XR-ODT under fasted conditions in children and adolescents by age. MPH XR-ODT, methylphenidate extended-release orally disintegrating tablets.
Quillivant Xr™, supplied by NextWave Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/metadate+cd+formulation/quillivant+xr/pmc04268556-90-9-11
Average 90 stars, based on 1 article reviews
quillivant xr™ - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
60mg multilayer-release mph aptensio xr  (Rhodes Pharmaceuticals)
90
Rhodes Pharmaceuticals 60mg multilayer-release mph aptensio xr
Mean total methylphenidate plasma concentration–time profiles for <t>MPH</t> XR-ODT under fasted conditions in children and adolescents by age. MPH XR-ODT, methylphenidate extended-release orally disintegrating tablets.
60mg Multilayer Release Mph Aptensio Xr, supplied by Rhodes Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/metadate+cd+formulation/60mg+multilayer+release+mph+aptensio+xr/pmc09507140-70-12-19
Average 90 stars, based on 1 article reviews
60mg multilayer-release mph aptensio xr - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mph er oral suspension [meros; quillivant xr  (Tris Pharma)
90
Tris Pharma mph er oral suspension [meros; quillivant xr
Comparison of mean <t>MPH</t> concentration (conc) time curves of single evening doses of DR/ER-MPH (20 and 100 mg) and single morning doses of OROS MPH (18, 36, and 54 mg), MPH CD (20, 40, and 60 mg), <t>d-MPH</t> <t>ER</t> (20 mg), and MEROS (60 mg). Evening-dosed DR/ER-MPH is assumed to be administered 10 hours before morning administration.
Mph Er Oral Suspension [Meros; Quillivant Xr, supplied by Tris Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/metadate+cd+formulation/quillivant+xr/pmc07343180-35-49-56
Average 90 stars, based on 1 article reviews
mph er oral suspension [meros; quillivant xr - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
multilayer-release mph  (Rhodes Pharmaceuticals)
90
Rhodes Pharmaceuticals multilayer-release mph
Comparison of mean <t>MPH</t> concentration (conc) time curves of single evening doses of DR/ER-MPH (20 and 100 mg) and single morning doses of OROS MPH (18, 36, and 54 mg), MPH CD (20, 40, and 60 mg), <t>d-MPH</t> <t>ER</t> (20 mg), and MEROS (60 mg). Evening-dosed DR/ER-MPH is assumed to be administered 10 hours before morning administration.
Multilayer Release Mph, supplied by Rhodes Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/metadate+cd+formulation/multilayer+release+mph/pmc09507140-70-14-19
Average 90 stars, based on 1 article reviews
multilayer-release mph - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Mean total methylphenidate plasma concentration–time profiles for MPH XR-ODT under fasted conditions in children and adolescents by age. MPH XR-ODT, methylphenidate extended-release orally disintegrating tablets.

Journal: Journal of Child and Adolescent Psychopharmacology

Article Title: A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

doi: 10.1089/cap.2015.0261

Figure Lengend Snippet: Mean total methylphenidate plasma concentration–time profiles for MPH XR-ODT under fasted conditions in children and adolescents by age. MPH XR-ODT, methylphenidate extended-release orally disintegrating tablets.

Article Snippet: The average T max (4.25–5.31 hours) for total MPH was similar (although not identical) for all age groups and was consistent with previous reports of other long-acting MPH formulations (Ritalin LA ® Novartis Pharmaceuticals Co., East Hanover, NJ; Metadate CD ® UCB Inc., Smyrna, GA).

Techniques: Clinical Proteomics, Concentration Assay

Mean total methylphenidate plasma concentration–time profiles for MPH XR-ODT under fasted conditions in children and adolescents. MPH XR-ODT, methylphenidate extended-release orally disintegrating tablets.

Journal: Journal of Child and Adolescent Psychopharmacology

Article Title: A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

doi: 10.1089/cap.2015.0261

Figure Lengend Snippet: Mean total methylphenidate plasma concentration–time profiles for MPH XR-ODT under fasted conditions in children and adolescents. MPH XR-ODT, methylphenidate extended-release orally disintegrating tablets.

Article Snippet: The average T max (4.25–5.31 hours) for total MPH was similar (although not identical) for all age groups and was consistent with previous reports of other long-acting MPH formulations (Ritalin LA ® Novartis Pharmaceuticals Co., East Hanover, NJ; Metadate CD ® UCB Inc., Smyrna, GA).

Techniques: Clinical Proteomics, Concentration Assay

Total Methylphenidate Pharmacokinetic Parameters of MPH XR-ODT

Journal: Journal of Child and Adolescent Psychopharmacology

Article Title: A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

doi: 10.1089/cap.2015.0261

Figure Lengend Snippet: Total Methylphenidate Pharmacokinetic Parameters of MPH XR-ODT

Article Snippet: The average T max (4.25–5.31 hours) for total MPH was similar (although not identical) for all age groups and was consistent with previous reports of other long-acting MPH formulations (Ritalin LA ® Novartis Pharmaceuticals Co., East Hanover, NJ; Metadate CD ® UCB Inc., Smyrna, GA).

Techniques:

Comparison of mean MPH concentration (conc) time curves of single evening doses of DR/ER-MPH (20 and 100 mg) and single morning doses of OROS MPH (18, 36, and 54 mg), MPH CD (20, 40, and 60 mg), d-MPH ER (20 mg), and MEROS (60 mg). Evening-dosed DR/ER-MPH is assumed to be administered 10 hours before morning administration.

Journal: Journal of Clinical Psychopharmacology

Article Title: Model-Based Approach for Establishing the Predicted Clinical Response of a Delayed-Release and Extended-Release Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder

doi: 10.1097/JCP.0000000000001222

Figure Lengend Snippet: Comparison of mean MPH concentration (conc) time curves of single evening doses of DR/ER-MPH (20 and 100 mg) and single morning doses of OROS MPH (18, 36, and 54 mg), MPH CD (20, 40, and 60 mg), d-MPH ER (20 mg), and MEROS (60 mg). Evening-dosed DR/ER-MPH is assumed to be administered 10 hours before morning administration.

Article Snippet: The model-based PK curves of DR/ER-MPH at 20 and 100 mg were then compared with those previously determined for other MPH ER formulations (ie, osmotic release oral system MPH [OROS MPH; Concerta, Janssen Pharmaceuticals, Inc, Titusville, New Jersey], MPH controlled-release delivery [MPH CD; Metadate CD, UCB, Inc, Smyrna, Georgia], MPH ER oral suspension [MEROS; Quillivant XR, Tris Pharma, Inc, Monmouth Junction, New Jersey], and extended-release dexmethylphenidate [d-MPH ER; Focalin XR, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey]) using a similar population PK modeling approach.

Techniques: Concentration Assay